Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: Are they comparable?

Surgery ◽  
2011 ◽  
Vol 150 (5) ◽  
pp. 980-984 ◽  
Author(s):  
Jung Wook Huh ◽  
Chang Hyun Kim ◽  
Hyeong Rok Kim ◽  
Young Jin Kim
2020 ◽  
Vol 18 (9) ◽  
pp. 1230-1237 ◽  
Author(s):  
Seyed M. Qaderi ◽  
Paul W. Dickman ◽  
Johannes H.W. de Wilt ◽  
Rob H.A. Verhoeven

Background: The increasing number of colorectal cancer (CRC) survivors need survival estimates that account for the time already survived. The aim of this population-based study was to determine conditional survival, cure proportions, and time-to-cure (TTC) of patients with colon or rectal cancer. Materials and Methods: All patients with pathologic stage I–III CRC treated with endoscopy or surgery, diagnosed and registered in the Netherlands Cancer Registry between 1995 and 2016, and aged 18 to 99 years were included. Conditional survival was calculated for those diagnosed before and after 2007. Cure proportions were calculated using flexible parametric models. Results: A total of 175,384 patients with pathologic stage I (25%), II (38%), or III disease (37%) were included. Conditional 5-year survival of patients with stage I, II, and III colon cancer having survived 5 years was 98%, 94%, and 92%, respectively. For patients with stage I–III rectal cancer, this was 96%, 89%, and 85%, respectively. Statistical cure in patients with colon cancer was reached directly after diagnosis (stage I) to 6 years (stage III) after diagnosis depending on age, sex, and disease stage. Patients with rectal cancer reached cure 0.5 years after diagnosis (stage I) to 9 years after diagnosis (stage III). In 1995, approximately 42% to 46% of patients with stage III colon or rectal cancer, respectively, were considered cured, whereas in 2016 this percentage increased to 73% to 78%, respectively. Conclusions: The number of patients with CRC reaching cure has increased substantially over the years. This study’s results provide valuable insights into trends of CRC patient survival and are important for patients, clinicians, and policymakers.


Surgery Today ◽  
2015 ◽  
Vol 46 (7) ◽  
pp. 852-859 ◽  
Author(s):  
Naohito Beppu ◽  
Hidenori Yoshie ◽  
Fumihiko Kimura ◽  
Tsukasa Aihara ◽  
Hiroshi Doi ◽  
...  

2016 ◽  
Vol 120 (2) ◽  
pp. 222-227 ◽  
Author(s):  
Takeo Sato ◽  
Kazushige Hayakawa ◽  
Naohiro Tomita ◽  
Masafumi Noda ◽  
Norihiko Kamikonya ◽  
...  

2019 ◽  
Vol 3 (1) ◽  
pp. 43-48
Author(s):  
Gaku Ohira ◽  
Hideaki Miyauchi ◽  
Koichi Hayano ◽  
Shunsuke Imanishi ◽  
Toru Tochigi ◽  
...  

2019 ◽  
Vol 269 (4) ◽  
pp. 678-685 ◽  
Author(s):  
Jae Hyuck Jang ◽  
Hee Cheol Kim ◽  
Jung Wook Huh ◽  
Yoon Ah Park ◽  
Yong Beom Cho ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15161-e15161 ◽  
Author(s):  
Dong Won Baek ◽  
Kyung Hwa Kim ◽  
Byung Woog Kang ◽  
Hye Jin Kim ◽  
Soo Yeon Park ◽  
...  

e15161 Background: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision has become the standard treatment for locally advanced rectal cancer (LARC). However, the effect of CRT varies from complete response to complete resistance, and predicting response to CRT have not been well characterized yet. Previous studies have shown the potential of micro-RNA (miRNA) based approaches to enhance tumor radiation response. Accordingly, the present study attempted to identify biomarkers to predict response for preoperative CRT using comprehensive miRNA analysis in patients with LARC. Methods: This study included 65 rectal cancer tissues and 90 serum samples from patients who diagnosed with LACR and received preoperative CRT at Kyungpook National University Chilgok Hospital. Tissue specimens and serum samples were collected before CRT to evaluate the biologic differences between the good CRT response group and the poor CRT response group. For discovery of specific miRNAs, 800 miRNAs were analyzed using NanoString in 30 rectal cancer tissues. Thereafter, a total of 65 tissues, and 90 serum samples were investigated using real-time PCR for validation. Results: The median age was 59 years (range, 30-82), and the ratio of male to female was 3.05 to 1. The pathologic stages after preoperative CRT were as follows: pathologic complete response (n=13, 14.4%), pathologic stage I (n=13, 14.4%), pathologic stage II (n=27, 30.0%), pathologic stage III (n=28, 31.1%), and pathologic stage IV (n=9, 10.0%). In the discovery set, 16 target miRNAs were detected. In the validation set with tissue specimens, expression of 3 miRNAs (miR-199a/b-3p ( p=0.032), miR-199a-5p ( p=0.023), miR-199b-5p ( p=0.005)) was significantly upregulated which was associated with better response of CRT. Moreover, among the 3 candidate miRNAs, miR-199b-5p level was significantly upregulated in serum, and it was also found to be related with better response of CRT in LARC (pathologic stage 0/I versus II/III/IV, p=0.027). Conclusions: In the present study, high level of exosomal miR-199b-5p was associated with better response, suggesting it to be a promising non-invasive biomarker to predict response of CRT in patients with LARC. Accordingly, specific miRNAs can be predictive biomarker or therapeutic target to overcome radiotherapy resistance in LARC with a functional study.


Sign in / Sign up

Export Citation Format

Share Document